{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:12:06Z","timestamp":1787987526376,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Research, Innovation, and Digitalization, CNCS-UEFISCDI","award":["PN-IV-P8-8.3-ROMD-2023-0259"],"award-info":[{"award-number":["PN-IV-P8-8.3-ROMD-2023-0259"]}]},{"name":"Grigore T. Popa University of Medicine and Pharmacy of Iasi, Romania"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04088-1","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:29:30Z","timestamp":1743506970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The prospect of novel orphan therapeutic protocol for TSC2\/PKD1 contiguous gene syndrome: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Bogdan D.","family":"Agavriloaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu C.","family":"Costache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0767-3692","authenticated-orcid":false,"given":"Ramona G.","family":"Babici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-0096","authenticated-orcid":false,"given":"Stela","family":"Racovi\u021b\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-6077","authenticated-orcid":false,"given":"Gianina","family":"Dodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-2486","authenticated-orcid":false,"given":"Adrian C.","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1173-2824","authenticated-orcid":false,"given":"Irina L.","family":"Mititiuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"4088_CR1","unstructured":"Harris PC, Torres VE. In: Adam MP, Feldman J, Mirzaa GM, et al. editors. Polycystic kidney disease, autosomal dominant. GeneReviews. University of Washington, Seattle; 2002."},{"key":"4088_CR2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/TCRM.S196244","volume":"15","author":"A Rastogi","year":"2019","unstructured":"Rastogi A, Ameen KM, Al-Baghdadi M, et al. Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 2019;15:1041\u201352.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"4088_CR3","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1007\/s00467-022-05820-x","volume":"38","author":"S Gallo-Bernal","year":"2023","unstructured":"Gallo-Bernal S, Kilcoyne A, Gee MS, Paul E. Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions. Pediatr Nephrol. 2023;38(10):3253\u201364.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"4088_CR4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/ki.2008.485","volume":"74","author":"MB Consugar","year":"2008","unstructured":"Consugar MB, Wong WC, Lundquist PA, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1\/TSC2 contiguous gene syndrome. Kidney Int. 2008;74(11):1468\u201379.","journal-title":"Kidney Int"},{"issue":"6","key":"4088_CR5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5414\/CN110476","volume":"97","author":"S Shang","year":"2022","unstructured":"Shang S, Mei Y, Wang T, et al. Diagnosis and genotype-phenotype correlation in patients with PKD1\/TSC2 contiguous gene deletion syndrome. Clin Nephrol. 2022;97(6):328\u201338.","journal-title":"Clin Nephrol"},{"key":"4088_CR6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, et al. Tolvaptan in Later-Stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"4088_CR7","doi-asserted-by":"crossref","first-page":"22257","DOI":"10.1038\/s41598-023-48638-9","volume":"13","author":"L Calvaruso","year":"2023","unstructured":"Calvaruso L, Yau K, Akbari P, et al. Real-life use of Tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort. Sci Rep. 2023;13:22257.","journal-title":"Sci Rep"},{"issue":"3","key":"4088_CR8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/2772432817666220517162012","volume":"18","author":"XE Guerra-Torres","year":"2023","unstructured":"Guerra-Torres XE. A case report of tuberous sclerosis and autosomal dominant polycystic kidney disease in the era of Tolvaptan. Curr Rev Clin Exp Pharmacol. 2023;18(3):284\u201390.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"5","key":"4088_CR9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13730-024-00854-6","volume":"13","author":"C Muroga","year":"2024","unstructured":"Muroga C, Yokoyama H, Kinoshita R, Fujimori D, Yamada Y, Okanishi T, Morisada N, Nozu K, Namba N. A child with TSC2\/PKD1 contiguous gene deletion syndrome successfully treated with Tolvaptan for rapidly enlarging renal cysts. CEN Case Rep. 2024;13(5):351\u20135.","journal-title":"CEN Case Rep"},{"key":"4088_CR10","doi-asserted-by":"crossref","unstructured":"Walz G, Budde K, Mannaa M, N\u00fcrnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, H\u00f6rl WH, Oberm\u00fcller N, Arns W, Pavenst\u00e4dt H, Gaedeke J, B\u00fcchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830\u201340. Erratum in: N Engl J Med. 2010;363(20):1977. Erratum in: N Engl J Med. 2010;363(12):1190.","DOI":"10.1056\/NEJMoa1003491"},{"key":"4088_CR11","doi-asserted-by":"crossref","unstructured":"Orosz P, Koll\u00e1k Z, Peth\u0151 \u00c1, Fogarasi A, Reusz G, Hadzsiev K, Szab\u00f3 T. The Importance of Genetic Testing in the Differential Diagnosis of Atypical TSC2-PKD1 Contiguous Gene Syndrome- Case Series. Children. 2023;10:420.","DOI":"10.3390\/children10030420"},{"issue":"1","key":"4088_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4088_CR13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","volume":"8","author":"PT Brook-Carter","year":"1994","unstructured":"Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease\u2013a contiguous gene syndrome. Nat Genet. 1994;8(4):328\u201332.","journal-title":"Nat Genet"},{"key":"4088_CR14","doi-asserted-by":"crossref","unstructured":"Dhakal M, Dhakal OP, Bhandari D. Polycystic kidney disease and chronic renal failure in tuberous sclerosis. BMJ Case Rep. 2013;2013:bcr2013200711.","DOI":"10.1136\/bcr-2013-200711"},{"issue":"5","key":"4088_CR15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller RU, Messchendorp AL, Birn H, et al. An update on the use of Tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international. Nephrol Dial Transpl. 2022;37(5):825\u201339.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4088_CR16","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE. 2016;11(6):e0158476.","journal-title":"PLoS ONE"},{"issue":"8","key":"4088_CR17","doi-asserted-by":"crossref","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8):e0180939.","journal-title":"PLoS ONE"},{"issue":"6","key":"4088_CR18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/1754-9485.13547","volume":"67","author":"S McQueen","year":"2023","unstructured":"McQueen S, Combes A, Benz D. Renal angiomyolipoma: beyond size criteria for predicting rupture. J Med Imaging Radiat Oncol. 2023;67(6):619\u201324.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"4088_CR19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15586\/jkcvhl.v9i1.177","volume":"9","author":"JC\u00c1 Restrepo","year":"2022","unstructured":"Restrepo JC\u00c1, Millan DAC, Sabogal CAR, Bernal AFP, Donoso WD. New trends and evidence for the management of renal angiomyolipoma: A comprehensive narrative review of the literature. J Kidney Cancer VHL. 2022;9(1):33\u201341.","journal-title":"J Kidney Cancer VHL"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04088-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:30:07Z","timestamp":1743507007000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04088-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4088"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04088-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Ethics Committee of the Grigore T. Popa University of Medicine and Pharmacy (no.394\/2024.02.01), Ia\u0219i, Romania. The study was conducted in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration and its later amendments. Written informed consent was obtained from the patient for participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication, including the use of anonymized patient data and images, were obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}